Drug intelligence / Profile preview

DWC202005

Development stage: Phase 1
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202005 is an orally administered investigational drug developed by Daewoong Pharmaceutical. It is classified as a new molecular entity, but its mechanism of action and therapeutic indication have not been publicly disclosed. The compound has undergone phase I clinical trials, including drug-drug interaction studies in healthy volunteers in Australia. As of the latest updates, no further development or specific disease indication has been reported[1][2][3].

Beyond the preview

Go deeper on DWC202005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202005.

Explore the full profile